Hansoh Pharmaceutical Group Company Limited

As of December 31, 2025, Hansoh Pharmaceutical Group Co Ltd. carries a market capitalization of 30.35B, placing it among publicly traded companies globally. Its enterprise value stands at 25.85B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Hansoh Pharmaceutical Group Co Ltd.'s next confirmed earnings release is scheduled for March 30, 2027.

As of December 31, 2025, Hansoh Pharmaceutical Group Co Ltd. has 6.05B shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Hansoh Pharmaceutical Group Co Ltd. maintains a current ratio of 8.09, meaning it holds 8.1x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 22, 2026, Hansoh Pharmaceutical Group Co Ltd.'s stock has declined approximately 15.00% over the past 52 weeks.

As of December 31, 2025, Hansoh Pharmaceutical Group Co Ltd. holds 4.51B in cash and equivalents against 15.03M in total debt, resulting in a net debt position of -4.51B. Total book value stands at 5.06B, with working capital of 4.46B providing operational flexibility.